Esperion Therapeutics, Inc.
ESPR Real Time Price USDRecent trades of ESPR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ESPR's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
ESPR Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Methods of making bempedoic acid and compositions of the same May. 21, 2024
-
Patent Title: Methods of making bempedoic acid and compositions of the same Mar. 12, 2024
-
Patent Title: Methods of making bempedoic acid and compositions of the same Sep. 19, 2023
-
Patent Title: Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease Sep. 05, 2023
-
Patent Title: Methods of making bempedoic acid and compositions of the same Mar. 28, 2023
-
Patent Title: Methods of making bempedoic acid and compositions of the same Aug. 09, 2022
-
Patent Title: Hydroxyl compounds and compositions for cholesterol management and related uses Mar. 09, 2021
-
Patent Title: Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease Feb. 09, 2021
-
Patent Title: Hydroxyl compounds and compositions for cholesterol management and related uses Nov. 06, 2018
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses Aug. 14, 2018
-
Patent Title: Hydroxyl compounds and compositions for cholesterol management and related uses Apr. 18, 2017
-
Patent Title: Apolipoprotein mixtures Apr. 04, 2017
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses Sep. 27, 2016
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses Apr. 14, 2015
-
Patent Title: Hydroxyl compounds and compositions for cholesterol management and related uses Apr. 07, 2015
-
Patent Title: Ketone compounds and compositions for cholesterol management and related uses Mar. 10, 2015
-
Patent Title: Ketone compounds and compositions for cholesterol management and related uses Feb. 04, 2014
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses Jan. 07, 2014
-
Patent Title: Hydroxyl compounds and compositions for cholesterol management and related uses Jul. 30, 2013
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses Nov. 13, 2012
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management Apr. 10, 2012
-
Patent Title: Ketone compounds and compositions for cholesterol management and related uses Dec. 27, 2011
-
Patent Title: Cycloalkyl-hydroxyl compounds and compositions for cholesterol management Nov. 29, 2011
-
Patent Title: Dihydroxyl compounds and compositions for cholesterol management and related uses Nov. 23, 2010
-
Patent Title: Hydroxyl compounds and compositions for cholesterol management and related uses Oct. 12, 2010
-
Patent Title: Compositions comprising ether compounds and pharmaceutical uses therefor May. 04, 2010
-
Patent Title: Ketone compounds and compositions for cholesterol management and related uses Apr. 27, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to ESPR
Number of mentions of ESPR in WallStreetBets Daily Discussion
Recent picks made for ESPR stock on CNBC
ETFs with the largest estimated holdings in ESPR
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ESPR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.